Menu
Recruiting NCT04183660

A Post Market Surveillance Study of the Hemovent Extracorporeal Cardiopulmonary Support System:The MOBYBOX Trial

— Observational Cardiac Failure Respiratory Failure Cardio-Respiratory Failure Imminent Cardiorespiratory or Respiratory Failure

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: MOBYBOX System.
Who it may be relevant to
Registry conditions: Cardiac Failure, Respiratory Failure, Cardio-Respiratory Failure, Imminent Cardiorespiratory or Respiratory Failure. Basic parameters: 18 years — 80 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Germany
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Post Market Surveillance Study of the Hemovent Extracorporeal Cardiopulmonary Support System for Cardiac and Respiratory Support: The MOBYBOX Trial

Overview

The purpose of this study is to evaluate prospectively the safety and performance of the MOBYBOX System in the veno-arterial configuration in patients with cardiorespiratory failure or in the veno-venous configuration in patients with severe respiratory failure.

Interventions

  • Device MOBYBOX System
    extracorporeal cardiopulmonary support

Primary outcome measures

  • Rates of device and procedure related serious adverse events [Time frame: 24 hours]
Secondary outcome measures (3)
  • Device performance success [Time frame: every 4 hours while the patient receives ECMO using the MOBYBOX device]
  • Adverse Event rate [Time frame: 24 hours]
  • Mortality rate [Time frame: 30 days]

Eligibility criteria

Inclusion criteria

  • Diagnosed with cardiac, respiratory or cardiorespiratory failure or imminent failure and 1 of the 5 following sets of findings:
  • A Murray score ≥ 3.0 and/or severe hypoxemia with A PaO2/FIO2 > 100 mm on 0.9 FIO2;
  • Uncompensated hypercapnia with pH <7.2 despite a Pplateau > 30 cm H20;
  • Significant air leak/bronchopleural fistula;
  • Need for intubation in a patient on lung transplant list;
  • Immediate/risk of cardiac or respiratory collapse (pulmonary embolus, blocked airway, blocked blood flow, unresponsive to optimal care);
  • Written consent of the patient or the legal guardian or external consulting physician as designated and approved by the Ethics Committee.

Exclusion criteria

  • High pressure ventilation (FIO2 > 0.9 and Pplateau > 30 cm H2O) or high FIO2 requirements for more than 7 days;
  • Severe intracranial bleeding, which precludes the use of anticoagulation therapy or any other inability to be anticoagulated
  • Excessive weight (> 180 Kg)
  • Severe irreversible brain injury (e.g., hypoxic brain injury)
  • Inability to accept blood products;
  • Any condition or organ dysfunction that would limit the likelihood of overall benefit from ECMO, such as severe, irreversible brain injury, hepatic and/or renal failure, or untreatable metastatic cancer;
  • Immunosuppression with an absolute neutrophil count < 400/mm3;
  • Patient has been treated with ECMO ≤ 48 hours.
  • For veno-veno ECMO in the setting of respiratory failure the following exclusion criteria apply:
  • Severe pulmonary hypertension (mPAP > 50 mm Hg)
  • Severe right or left sided heart failure (EF < 25%)
  • For veno-arterial ECMO in the setting of cardiac insufficiency:
  • Severe aortic regurgitation
  • Aortic dissection.
  • The patient is moribund, or the patient has severe or deteriorating damage in critical body systems.
  • Patient is participating in an investigational drug or device study trial that has not reached the primary endpoint or that interferes with the current study endpoints.
  • Any condition that in the judgment of the investigators would interfere with the subject's ability to provide informed consent, comply with study instructions, place the subject at increased risk, or which might confound interpretation of study results.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Case-only

Study locations

Germany · 4 centers
  • Medizinische Hochschule Hannover — Hanover
  • Universitätsklinikum Essen — Essen
  • Universitätsklinikum Halle — Halle
  • Helios Klinikum Erfurt — Erfurt

Identifiers

NCT: NCT04183660 · HVT-MB1

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗